UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2024

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

288 Grove Street, Suite 388
Braintree, MA 02184
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 24, 2024, Microbot Medical Inc. (the "Company") posted updated presentation materials on its website.

The presentation materials can be accessed via the 'Investors' section, under 'IR Resources' and then 'Additional Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

The presentation materials are also furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 8.01 Other Events.

The Company currently anticipates receiving 510(k) clearance from the US Food & Drug Administration in the first half of 2025, and CE Mark approval in the second half of 2025.

Forward Looking Statements

This Item 8.01 of this Current Report on Form 8-K contains "forward-looking statements." Such statements which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: April 24, 2024

Exhibit 99.1

FORWARD LOOKING STATEMENT

This presentation (together with any oral statements made in connection herewith, the "Presentation"), is provided for informational purposes only and has been prepared to assist interested parties in evaluating Microbot Medical Inc. ("Microbot") and for no other purpose.

This Presentation does not constitute or include an offer to sell, or a solicitation of an offer to purchase or subscribe for, securities of any kind, nor shall there be any sale, issuance or transfer of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any such offer or solicitation will be made only in connection with the delivery of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or exemptions therefrom.

No representation, express or implied, is or will be given by Microbot or its affiliates and advisors as to the accuracy or completeness of the information contained in this Presentation.

This Presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "may," "can," "will," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends that are not statements of historical matters. Such forward-looking statements with respect to revenues, earnings, performance, strategies, timelines, the market, prospects and other aspects of the business of Microbot are based on current expectations that are subject to risks and uncertainties. A number of factors, many of which are outside of the control of Microbot, could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY® Endovascular Robotic Surgical System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether Microbot succeeds in obtaining FDA approval to commence its pivotal study in humans, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot can be found under the heading "Risk Factors" in Microbot's periodic reports filed with the Securities and Exchange Commission ("SEC"), which are available on the SEC's web site at www.sec.gov. Microbot disclaims any intent or obligation to update these forward-looking statements, except as required by law.


SURGICAL ROBOTICS TODAY
Large and cumbersome footprint
Dedicated room and dedicated staff
Time consuming to set up and use
Long and expensive learning curve

ENDO-VASCULAR: TOTAL ADDRESSABLE MARKET (US)



[1] Medtech 360 Reports

SUPPORTED BY INTERVENTIONALISTS

Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future?



N=200 interventionalists, data on file

ENDO-VASCULAR ROBOTICS: LIMITED ADOPTION



[1] Deduced from Public Records

MULTIPLE BARRIERS LEADING TO LOW PENETRATION

Extended set-up time

Special training, long learning curve

Large footprint

Capital expense

Cumbersome and expensive disposables

Dedicated infrastructure


ELIMINATING BARRIERS, ALLOWING ACCESS
microbot
medical

ELIMINATING BARRIERS, ALLOWING ACCESS

Disposable
- No capital expense
- Increases procedure efficiency

Small Footprint
- Compact & Light
- No dedicated infrastructure

Mobile
- Utilized in multiple sites of service

Remote
- Reduce exposure to radiation*
- Eliminate user physical strain*
- Telesurgery enabled

Universal
- Compatible with off-the-shelf instruments

*When operating seated away from radiation source

ACCESS-ABILITY FOR ALL™



NO MATTER WHAT • NO MATTER WHERE • NO MATTER WHO

LIBERTY PRODUCT LIFECYCLE (CURRENT)

LIBERTY

Open System

- Compatible with all OEM devices
- Initial focus on peripheral vascular procedures
- Expand to include neuro-vascular and coronary applications

INITIAL TARGET THERAPIES

- **Embolotherapy (Peripheral Vascular)**
  - Interventional Oncology
  - MSK
  - Others



REGULATORY STATUS

FDA

510(k) Clearance anticipated H1 2025

CE CERTIFIED

Anticipated H2 2025

LIBERTY PRODUCT LIFECYCLE*

LIBERTY

Open System

- Compatible with all OEM devices
- Initial focus on peripheral vascular procedures
- Expand to include neuro-vascular and coronary applications

LIBERTY+™

Remote Enabled

- 5G/WiFi enabled
- Integration into multiple site/satellite locations
- Enable remote procedures, proctoring, training

*Under evaluation (internally & via clinical partner)

LIBERTY PRODUCT LIFECYCLE**

LIBERTY

Open System

- Compatible with all OEM devices
- Initial focus on peripheral vascular procedures
- Expand to include neuro-vascular and coronary applications

LIBERTY+

Remote Enabled

- 5G/WiFi enabled
- Integration into multiple site/satteliet locations
- Enable remote procedures, proctoring, training

LIBERTY MAX ™

Autonomous Procedures

- Plan, Monitor, Insert, Steer
- Compatibility with CBCT with 3D imaging
- Compatibility with Navigation system
- AI/ML Integration

**Potential long-term future offering